CXCL8 and rheumatoid arthritis: demonstrated that treatment with TNFα neutralizing antibody can significantly suppress the expression of other pro-inflammatory cytokines in inflamed RA joints, such as IL-1β, IL-6, IL-8 and granulocyte monocyte-colony stimulating factor (GM-CSF), and attenuate pathological signs in the RA mouse model (33–37).